EO9 (Apaziquone): from the clinic to the laboratory and back again

Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4

(2011) Saskia E Rademakers et al.   BMC CANCER

Intraperitoneal therapy for peritoneal cancer

(2010) Ze Lu et al.   Future Oncology

Marker Lesion Experiments in Bladder Cancer—What Have We Learned?

(2010) Ofer N. Gofrit et al.   JOURNAL OF UROLOGY

Synthesis and Evaluation of Stable Bidentate Transition Metal Complexes of 1-(Chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (seco-6-azaCBI-TMI) as Hypoxia Selective Cytotoxins

(2009) Jared B. J. Milbank et al.   JOURNAL OF MEDICINAL CHEMISTRY

Hypoxia-Activated Prodrugs: Substituent Effects on the Properties of Nitroseco-1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) Prodrugs of DNA Minor Groove Alkylating Agents

(2009) Moana Tercel et al.   JOURNAL OF MEDICINAL CHEMISTRY

Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence

(2009) Wim P. Ceelen et al.   Nature Reviews Clinical Oncology

Response of Multiple Recurrent TaT1 Bladder Cancer to Intravesical Apaziquone (EO9): Comparative Analysis of Tumor Recurrence Rates

(2009) Arun Jain et al.   UROLOGY

Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer

(2009) Kees Hendricksen et al.   WORLD JOURNAL OF UROLOGY

Tricyclic [1,2,4]Triazine 1,4-Dioxides As Hypoxia Selective Cytotoxins

(2008) Michael P. Hay et al.   JOURNAL OF MEDICINAL CHEMISTRY

Safety and Side Effects of Immediate Instillation of Apaziquone Following Transurethral Resection in Patients With Nonmuscle Invasive Bladder Cancer

(2008) K. Hendricksen et al.   JOURNAL OF UROLOGY